Skip to main content
Premium Trial:

Request an Annual Quote

Athanasios Maroglou, Len van Zyl, Dile Holton, Steve Bolze


Athanasios Maroglou, president and chief operating officer of Ercole Biotech of Research Triangle Park, NC, has joined the board of directors for Array Xpress, the Raleigh, NC-based microarray services startup spinning out of North Carolina State University to commercialize microarray technology developed by Len van Zyl, an assistant professor in the school's forest biotechnology group. Maroglou is also president of Thalima, a life science venture development company. Previously, he was vice president of project management for RTP-based Paradigm Genetics. He holds a PhD and a BSc in chemical engineering from the University of Birmingham, UK.

Dile Holton has joined MicroCal of Northampton, Mass., as marketing manager. Previously, Holton was a product manager for PerkinElmer Life and Analytical Sciences and involved in industry microarray standardization efforts.

Steve Bolze, 40, has been named General Electric’s vice president for Amersham integration planning. Bolze joined GE Medical Systems in 2002 as general manager, global functional and molecular imaging. Previously, Steve held several roles within GE Power Systems. Bolze joined GE in 1993. He holds a BS in electrical engineering from Duke University, and an MBA from the University of Michigan.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more